GHRS GH Research PLC

BEARISH Impact: 6/10 424B5
Horizon days Filed Apr 29, 2026 Processed 1mo ago SEC 0001140361-26-017654
Notable filing: 424B5
Latest settled — T+20d
GHRS ▲ +16.70% at T+20d
SHORT call ✗ call lost -16.70% · α vs SPY -11.24% · entry $19.16 → $22.36
Next anchor: T+60d in 6w
Last close $20.12 (close Jun 8) · -5.01% from $19.16 entry (call sign-flipped)
Entry anchored
Apr 28, 03:59 PM ET
via Databento tick
T+1d
+7.15%
call -7.15% · α -6.13%
$20.53
settled 6w ago
T+5d
+11.06%
call -11.06% · α -7.95%
$21.28
settled 5w ago
T+20d
+16.70%
call -16.70% · α -11.24%
$22.36
settled 13d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

GH Research PLC priced a follow-on offering of 6,527,779 ordinary shares at $18.00 per share, a 9.3% discount to the prior close of $19.85, raising net proceeds of approximately $111.2 million. The proceeds will fund R&D and general corporate purposes. The 10.5% dilution and the discount create near-term selling pressure, though the strong cash position and positive Phase 2b data support the long-term thesis.

Actionable Insight

Expect near-term pressure from the 9.3% discount and dilution. However, the $111M cash runway funds pivotal trials and the lock-up on 85.5% of shares reduces overhang. Watch for analyst reactions and the next clinical catalyst.

Key Facts

  • Offering of 6,527,779 ordinary shares at $18.00 per share
  • Net proceeds of approximately $111.2 million
  • Dilution of $12.30 per share for new investors (offering price minus adjusted net tangible book value of $5.70)
  • Immediate post-offering shares outstanding: 68,557,174
  • 30-day lock-up on 85.5% of shares held by insiders and major shareholders

Financial Impact

Approximately 10.5% dilution; $111.2 million raised, representing ~9.3% of market cap at offer price

dilutioncash balanceshares outstanding

Risk Factors

  • Further dilution if additional equity needs arise
  • Clinical trial setbacks could pressure stock
  • High insider concentration (85.5%) limits free float

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001140361-26-017654
Document: 0001140361-26-017654-index-headers.html0001140361-26-017654
Document: 0001140361-26-017654-index.html0001140361-26-017654
Document: 0001140361-26-017654.txt0001140361-26-017654
8 reports for GHRS
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+60▲ +63.68%Mar 5, 2026
Filters
Rows
Reports for GHRS — sortable, filterable
Type Now
May 14, 2026
26d ago
424B5
BEARISH ★ 6/10
$22.21 $21.77▲ +1.98%▲ +1.26%$20.12 (+9.41%)
May 14, 2026
26d ago
6-K
NEUTRAL ★ 5/10
$22.21 $21.77▼ −1.98%▼ −1.26%$20.12 (−9.41%)
May 14, 2026
26d ago
Press Release
MIXED ★ 6/10
$22.21 $21.77▼ −1.98%▼ −1.26%$20.12 (−9.41%)
May 13, 2026
27d ago
6-K
BEARISH ★ 6/10
$22.21 $21.77▲ +1.98%▲ +1.26%$20.12 (+9.41%)
Apr 29, 2026
5w ago
424B5
BEARISH ★ 6/10
$19.16 $21.28▼ −11.06%▼ −7.95%$20.12 (−5.01%)
Apr 1, 2026
9w ago
3
NEUTRAL ★ 2/10
$14.57 $15.72▲ +7.89%▲ +4.27%$20.12 (+38.09%)
Mar 25, 2026
10w ago
Press Release
BULLISH ★ 8/10
$13.65 $14.72▲ +7.84%▲ +8.08%$20.12 (+47.40%)
Mar 5, 2026
13w ago
Press Release
BULLISH ★ 8/10
$15.17 $15.52▲ +2.31%▲ +4.54%$20.12 (+32.63%)
Showing 8 of 8

US Market Status

Market Closed — Opens in 6h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access